ResMed Inc.
RMD · NYSE
Company research
ResMed Inc. (NYSE: RMD) is a San Diego-based global leader in digital health technology, specializing in the development, manufacturing, and distribution of cloud-connected medical devices and software solutions for the diagnosis, treatment, and management of sleep-disordered breathing, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Founded in 1989 and led by Chairman and CEO Michael J. Farrell, the company operates through two primary segments — Sleep and Breathing Health, which encompasses CPAP/bilevel devices, masks, and accessories, and Residential Care Software (SaaS), which includes enterprise platforms such as Brightree, MatrixCare, and MEDIFOX DAN serving out-of-hospital care settings. With over 28 million cloud-connected devices deployed across more than 140 countries and a recurring revenue model driven by consumables and software subscriptions, ResMed has successfully evolved from a traditional medical device manufacturer into a comprehensive digital health ecosystem. As of its most recent reporting period, the company employed approximately 9,980 full-time staff and held a market capitalization of approximately $29.6 billion.
Research reports
StockStory · July 5, 2026ResMed (RMD) Research Report
StockStory’s updated Q1 CY2026 report frames ResMed as a high‑quality compounder, highlighting 10.8% year‑on‑year revenue growth to about 1.43 billion, EPS of 2.86 beating consensus, strong operating and free‑cash‑flow margins, and a one‑year consensus price target around 270.6 implying roughly 30% upside; the note emphasizes resilient demand for sleep and respiratory devices and SaaS, while flagging GLP‑1 therapies, Philips’ return, and valuation sensitivity as key risks.
Flash (StockSentinel / Flash) · May 5, 2026ResMed Inc. (RMD) Stock Research ReportFlash’s long‑form report argues that ResMed’s cloud‑connected CPAP plus SaaS ecosystem is evolving into a “sticky, high‑margin data flywheel,” with scenario analysis yielding a weighted 5‑year price target around 380 versus a current price near 205 and projecting double‑digit EPS growth driven by recurring masks, software, and expanding sleep and respiratory markets; it explicitly lays out bull, base, and bear cases and details major risks including GLP‑1‑driven market shrinkage, Philips Respironics’ re‑entry, M&A execution (Noctrix), regulatory/cybersecurity exposure, and CFO succession.
Simply Wall St · June 21, 2026ResMed (NYSE:RMD) – Stock AnalysisSimply Wall St’s analysis presents ResMed as trading roughly 30% below its intrinsic fair‑value estimate, with earnings forecast to grow about 8–10% per year and margins and returns on capital well above peers, and notes that analyst price targets clustered around the high‑200s support a view that the stock is undervalued despite recent downgrades; the narrative acknowledges GLP‑1 competition, Philips’ eventual recovery, and valuation concerns but concludes that ResMed remains a fundamentally strong, cash‑generative business with attractive long‑term upside.
IG (IG Australia – Macro Intelligence, Authored By Juliette Saly) · August 6, 2025Innovative health solutions boost ResMed’s FY2025 performance (Macro Intelligence)IG’s Macro Intelligence deep‑dive reviews FY2025 results, highlighting a 10% revenue increase to about 5.15 billion, a 37% jump in net income to roughly 1.4 billion, margin expansion, and a 13% dividend hike to 0.60 per quarter, and cites brokers such as Morgan Stanley and Citi maintaining overweight/buy stances with average targets around 47–49 (ASX‑line), framing the stock as in a strong bullish trend; it also discusses how earlier GLP‑1 fears have eased as data suggest these drugs may complement, rather than cannibalize, CPAP usage, while noting competitive and GLP‑1‑related uncertainties as ongoing risks.